Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANAB NASDAQ:BCEL NASDAQ:CPRX NASDAQ:FULC NYSE:MNK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANABAnaptysBio$24.25+3.4%$22.04$12.21▼$41.31$688.97M-0.27642,773 shs1.03 million shsBCELAtreca$0.09$0.09$0.05▼$1.20$3.57M1.034.61 million shsN/ACPRXCatalyst Pharmaceuticals$20.75-1.0%$23.61$15.19▼$26.58$2.56B0.661.12 million shs1.40 million shsFULCFulcrum Therapeutics$7.85+11.8%$6.51$2.32▼$10.13$378.93M2.37911,735 shs1.17 million shsMNKMallinckrodt$0.34$0.75▼$6.42$1.58MN/A2.62 million shs39,227 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANABAnaptysBio+3.41%+7.06%+2.32%+43.49%-4.79%BCELAtreca0.00%0.00%0.00%0.00%0.00%CPRXCatalyst Pharmaceuticals-0.95%-2.08%-19.79%-8.75%+34.30%FULCFulcrum Therapeutics+11.82%+14.77%+8.28%+172.57%+29.75%MNKMallinckrodt0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANABAnaptysBio2.2778 of 5 stars3.41.00.00.02.12.50.6BCELAtrecaN/AN/AN/AN/AN/AN/AN/AN/ACPRXCatalyst Pharmaceuticals4.8957 of 5 stars3.61.00.03.92.73.33.8FULCFulcrum Therapeutics0.2064 of 5 stars1.30.00.00.00.62.50.0MNKMallinckrodtN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANABAnaptysBio 2.80Moderate Buy$42.3874.74% UpsideBCELAtreca 0.00N/AN/AN/ACPRXCatalyst Pharmaceuticals 3.25Buy$32.8358.23% UpsideFULCFulcrum Therapeutics 2.50Moderate Buy$6.29-19.93% DownsideMNKMallinckrodt 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest MNK, FULC, CPRX, ANAB, and BCEL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/5/2025CPRXCatalyst PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy6/4/2025ANABAnaptysBioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$22.00 ➝ $38.005/29/2025FULCFulcrum TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$6.00 ➝ $9.005/29/2025ANABAnaptysBioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$40.005/28/2025ANABAnaptysBioGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$54.00 ➝ $90.005/23/2025FULCFulcrum TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy5/23/2025FULCFulcrum TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$4.00 ➝ $12.005/15/2025FULCFulcrum TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Overweight$10.005/6/2025ANABAnaptysBioGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$52.00 ➝ $54.005/1/2025ANABAnaptysBioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$40.00 ➝ $40.00(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANABAnaptysBio$91.28M7.81N/AN/A$2.33 per share10.41BCELAtrecaN/AN/AN/AN/A$2.01 per shareN/ACPRXCatalyst Pharmaceuticals$491.73M5.15$2.42 per share8.56$6.10 per share3.40FULCFulcrum Therapeutics$80M5.30N/AN/A$4.51 per share1.74MNKMallinckrodtN/AN/AN/AN/A$47.48 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANABAnaptysBio-$145.23M-$4.85N/AN/AN/A-125.70%-282.47%-30.79%8/4/2025 (Estimated)BCELAtreca-$97.16M-$2.50N/AN/AN/AN/A-157.90%-71.39%N/ACPRXCatalyst Pharmaceuticals$163.89M$1.5713.229.740.8536.91%42.45%36.59%8/6/2025 (Estimated)FULCFulcrum Therapeutics-$9.73M-$0.07N/AN/AN/AN/A-0.20%-0.19%7/30/2025 (Estimated)MNKMallinckrodtN/A-$116.19N/AN/AN/A-82.59%20.32%2.49%N/ALatest MNK, FULC, CPRX, ANAB, and BCEL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025CPRXCatalyst Pharmaceuticals$0.57N/AN/AN/A$140.42 millionN/A8/4/2025Q2 2025ANABAnaptysBio-$1.47N/AN/AN/A$11.55 millionN/A7/30/2025Q2 2025FULCFulcrum Therapeutics-$0.29N/AN/AN/AN/AN/A5/5/2025Q1 2025ANABAnaptysBio-$1.30-$1.28+$0.02-$1.28$15.27 million$27.77 million5/1/2025Q1 2025FULCFulcrum Therapeutics-$0.29-$0.28+$0.01-$0.28N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANABAnaptysBioN/AN/AN/AN/AN/ABCELAtrecaN/AN/AN/AN/AN/ACPRXCatalyst PharmaceuticalsN/AN/AN/AN/AN/AFULCFulcrum TherapeuticsN/AN/AN/AN/AN/AMNKMallinckrodtN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANABAnaptysBioN/A8.258.25BCELAtrecaN/A1.581.58CPRXCatalyst PharmaceuticalsN/A6.145.96FULCFulcrum TherapeuticsN/A28.7128.71MNKMallinckrodt1.180.570.31Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANABAnaptysBioN/ABCELAtreca37.47%CPRXCatalyst Pharmaceuticals79.22%FULCFulcrum Therapeutics89.83%MNKMallinckrodt83.74%Insider OwnershipCompanyInsider OwnershipANABAnaptysBio33.50%BCELAtreca11.30%CPRXCatalyst Pharmaceuticals10.40%FULCFulcrum Therapeutics7.00%MNKMallinckrodt0.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANABAnaptysBio10029.38 million19.54 millionOptionableBCELAtreca13039.62 million35.15 millionOptionableCPRXCatalyst Pharmaceuticals80121.97 million109.29 millionOptionableFULCFulcrum Therapeutics10053.98 million50.20 millionOptionableMNKMallinckrodt2,70013.17 million13.13 millionNot OptionableMNK, FULC, CPRX, ANAB, and BCEL HeadlinesRecent News About These CompaniesMallinckrodt's $7B deal to merge with drugmaker Endo advancesJune 27, 2025 | bizjournals.comMallinckrodt, Endo shareholders approve combinationJune 24, 2025 | drugstorenews.comDMallinckrodt, Endo announce leadership for merged companyJune 18, 2025 | drugstorenews.comDMallinckrodt and Endo Shareholders Approve MergerJune 16, 2025 | msn.comMallinckrodt and Endo Announce Leadership Plans for Transformative MergerJune 14, 2025 | msn.comMallinckrodt plc: Mallinckrodt, Endo Announce Planned Leadership Team for Merged CompanyJune 9, 2025 | finanznachrichten.deMallinckrodt and Endo Advance Key Milestones in Strategic MergerMay 19, 2025 | msn.comMalvern-Based Endo Progresses Toward Mallinckrodt Merger CompletionMay 15, 2025 | msn.comMallinckrodt and Endo Announce Significant Progress in Proposed MergerMay 14, 2025 | finance.yahoo.comEndo, Inc.: Endo Reports First-Quarter 2025 Financial Results and Reaffirms 2025 Financial GuidanceMay 7, 2025 | finanznachrichten.deMalvern-Based Endo Approves $3.5M in Retention Bonuses for Executives Ahead of MergerApril 29, 2025 | msn.comEndo board approves millions in bonuses to keep key execs amid Mallinckrodt mergerApril 21, 2025 | bizjournals.comMallinckrodt plc to Report Earnings Results for First Quarter 2025April 10, 2025 | finance.yahoo.comMalvern’s Endo Enters Into Agreement to Merge with Mallinckrodt in $6 Billion DealMarch 17, 2025 | msn.comMallinckrodt, a pharmaceutical giant launched in St. Louis, to take over Endo in $6.7B dealMarch 17, 2025 | stltoday.comSMallinckrodt and Endo Announce Merger to Build Diversified Pharmaceuticals PowerhouseMarch 16, 2025 | msn.comMallinckrodt and Endo to combine after emerging from bankruptcy linked to opioid crisisMarch 15, 2025 | ft.comPharma Firms Mallinckrodt and Endo Agree to Merge in $6.7B Cash and Stock DealMarch 15, 2025 | msn.comTroubled drugmakers Mallinckrodt, Endo Officially Announce $6.7B MergerMarch 13, 2025 | biospace.comBDrugmakers Mallinckrodt and Endo to merge in nearly $7 billion dealMarch 13, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMNK, FULC, CPRX, ANAB, and BCEL Company DescriptionsAnaptysBio NASDAQ:ANAB$24.25 +0.80 (+3.41%) Closing price 07/8/2025 04:00 PM EasternExtended Trading$24.18 -0.07 (-0.31%) As of 08:28 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.Atreca NASDAQ:BCELAtreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. The company was incorporated in 2010 and is based in San Carlos, California.Catalyst Pharmaceuticals NASDAQ:CPRX$20.75 -0.20 (-0.95%) Closing price 07/8/2025 04:00 PM EasternExtended Trading$20.90 +0.15 (+0.72%) As of 08:31 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.Fulcrum Therapeutics NASDAQ:FULC$7.85 +0.83 (+11.82%) Closing price 07/8/2025 04:00 PM EasternExtended Trading$7.59 -0.26 (-3.31%) As of 08:10 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Mallinckrodt NYSE:MNKMallinckrodt Plc is a global specialty pharmaceuticals company. It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the Specialty Brands and Specialty Generics segments. The Specialty Brands segment includes branded medicines. The Specialty Generics segment relates to specialty generic drugs, active pharmaceutical ingredients, as well as external manufacturing. The company was founded by Gustavo Mallinckrodt, Otto Mallinckrodt and Edward Mallinckrodt in 1867 and is headquartered in Blanchardstown, Dublin. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Amazon's Prime Day Pullback Meets Bullish Golden Cross Signal Is Fortinet Ready to Break Out After Months of Consolidation? AST SpaceMobile: Is Market Noise Drowning Out a $100M Signal? CoreWeave's $9 Billion Power Play for Core Scientific Taiwan Semiconductor May Profit from Chinese Manufacturing Issues Micron Insiders Sell But Investors Should Buy, Buy, Buy Believe the Hype? Can SoFi Maintain Its 3-Month Rally? Sizzling Insider Buys for Your High-Yield Watchlist Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
